BioNTech Bags Bargain With Neon Buy
Expands Cell Therapy Pipeline
Neon listed on the NASDAQ at $16 per share 18 months ago. It has now been picked up by the ambitious German biotech for just $2.18 per share, having recently ended its cancer vaccine programs and laid off a quarter of its workforce.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The Bill & Melinda Gates Foundation has invested $55m in an infectious disease collaboration with Germany’s BioNTech that could reach up to $100m in total funding.
Mainz-based BioNTech raises $325m in an upsized series B round to further advance its individualized immuno-oncology pipeline and manufacturing infrastructure.